Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy

C-H Liu
February 2009
Gut;Feb2009, Vol. 58 Issue 2, p314
Academic Journal
The article discusses a study on the retreatment of dialysis chronic hepatitis C (CHC) patients who relapsed from interferon monotherapy using pegylated interferon and low-dose ribavirin. It explores the sustained virological response (SVR) and treatment-related withdrawal rates using pegylated IFN relapsers. It shows that pegylated IFN with low-dose ribavirin could have a potential SVR rate, while pretreatment of viral load and rapid virological response (RVR) are predictive factors of SVR.


Related Articles

  • Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. Nomura, Hideyuki; Miyagi, Yugo; Tanimoto, Hironori; Higashi, Masashi; Ishibashi, Hiromi // Journal of Gastroenterology;2009, Vol. 44 Issue 4, p338 

    The rates of sustained virologic response (SVR) and relapse with pegylated interferon alpha 2b (peginterferon) plus ribavirin in patients with genotype-1 chronic hepatitis C (CHC) are approximately 50 and 30%, respectively. We investigated whether SVR and transient response (TR) can be...

  • Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. Kogure, Takayuki; Ueno, Yoshiyuki; Fukushima, Koji; Nagasaki, Futoshi; Kondo, Yasuteru; Inoue, Jun; Matsuda, Yasunori; Kakazu, Eiji; Yamamoto, Takeshi; Onodera, Hiroyoshi; Miyazaki, Yutaka; Okamoto, Hiromasa; Akahane, Takehiro; Kobayashi, Tomoo; Mano, Yutaka; Iwasaki, Takao; Ishii, Motoyasu; Shimosegawa, Tooru; Essaid, Abdellah; Rai, Ramesh Roop // World Journal of Gastroenterology;12/21/2008, Vol. 14 Issue 47, p7225 

    AIM: To evaluate the efficacy of pegylated interferon α-2b (peg-IFNα-2b) plus ribavirin (RBV) therapy in Japanese patients with chronic hepatitis C (CHC) genotype Ib and a high viral load. METHODS: One hundred and twenty CHC patients (58.3% male) who received peg-IFNα-2b plus RBV...

  • Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. Kim, Soo; El-Shamy, Ahmed; Imoto, Susumu; Kim, Ke; Ide, Yoshi-hiro; Deng, Lin; Shoji, Ikuo; Tanaka, Yasuhito; Hasegawa, Yutaka; Ota, Mitsuhiro; Hotta, Hak // Journal of Gastroenterology;Oct2012, Vol. 47 Issue 10, p1143 

    Background: This study explores pretreatment predictive factors for ultimate virological responses to pegylated interferon-α (1.5 μg/kg/week) and ribavirin (600-1000 mg/day) (PEG-IFN/RBV) combination therapy for patients infected with hepatitis C virus (HCV)-1b and a high viral load....

  • Host factors determining the efficacy of hepatitis C treatment. Chuang, Wan-Long; Yu, Ming-Lung // Journal of Gastroenterology;Jan2013, Vol. 48 Issue 1, p22 

    Combination therapy with pegylated interferon and ribavirin is the standard of care (SOC) for the treatment of chronic hepatitis C (CHC). Treating CHC with SOC may show a sustained virological response (SVR) in approximately 50-70 % of genotype 1 CHC patients and an SVR in 70-90 % of genotype 2...

  • Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. Kurosaki, Masayuki; Sakamoto, Naoya; Iwasaki, Manabu; Sakamoto, Minoru; Suzuki, Yoshiyuki; Hiramatsu, Naoki; Sugauchi, Fuminaka; Yatsuhashi, Hiroshi; Izumi, Namiki // Journal of Gastroenterology;Mar2011, Vol. 46 Issue 3, p401 

    Background: This study aimed to develop a model for the pre-treatment prediction of sustained virological response (SVR) to peg-interferon plus ribavirin therapy in chronic hepatitis C. Methods: Data from 800 genotype 1b chronic hepatitis C patients with high viral load (>100,000 IU/ml) treated...

  • Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy. Sood, Ajit; Midha, Vandana; Goyal, Omesh // Annals of Hepatology: Official Journal of the Mexican Associatio;Sep/Oct2014, Vol. 13 Issue 5, p503 

    Introduction. Standard treatment for patients with chronic hepatitis C genotype 1 (CHC G-1) infection includes pegylated interferon plus ribavirin (PEG-RBV) for 48 weeks. Shorter treatment regimen would be more acceptable due to lower cost and fewer side-effects. We aimed to compare the efficacy...

  • Hepatitis C treatment in patients with kidney disease. Fabrizi, Fabrizio; Aghemo, Alessio; Messa, Piergiorgio // Kidney International;Nov2013, Vol. 84 Issue 5, p874 

    Hepatitis C virus (HCV) remains the most common cause of liver damage in patients with kidney disease, including those on long-term dialysis. The natural history of HCV in patients on regular dialysis is not fully elucidated, but an adverse effect of HCV on survival has been noted; a novel...

  • Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy. Sidharthan, Sreetha; Kohli, Anita; Sims, Zayani; Nelson, Amy; Osinusi, Anu; Masur, Henry; Kottilil, Shyam // Clinical Infectious Diseases;Jun2015, Vol. 60 Issue 12, p1743 

    Background: Hepatitis C virus (HCV) RNA loads serve as predictors of treatment response during interferon-based therapy. We evaluated the predictive ability of HCV RNA levels at end of treatment (EOT) for sustained virologic response (SVR12) during interferon-sparing direct-acting antiviral...

  • Interferon affacon-1.  // Formulary;May2005, Vol. 40 Issue 5, p168 

    Reports on successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin.


Read the Article


Sign out of this library

Other Topics